Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma

Blood

Volumn 125, Issue 7, 2015, Pages 1137-1145

  Iqbal, Javeed ^a   Shen, Yulei ^a   Huang, Xin ^a   Liu, Yanyan ^a   Wake, Laura ^a   Liu, Cuiling ^a   Deffenbacher, Karen ^a   Lachel, Cynthia M ^a   Wang, Chao ^a   Rohr, Joseph ^a   Guo, Shuangping ^a   Smith, Lynette M ^b   Wright, George ^c   Bhagavathi, Sharathkumar ^a   Dybkaer, Karen ^d   Fu, Kai ^a   Greiner, Timothy C ^a   Vose, Julie M ^b   Jaffe, Elaine ^c   Rimsza, Lisa ^e   Rosenwald, Andreas ^f   Ott, German ^g   Delabie, Jan ^h   Campo, Elias ⁱ   Braziel, Rita M ^j   Cook, James R ^k   Tubbs, Raymond R ^k   Armitage, James O ^b   Weisenburger, Dennis D ^l   Staudt, Louis M ^c   Gascoyne, Randy D ^m   McKeithan, Timothy W ^a,l   Chan, Wing C ^a,l   more..

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLOBOTRIAOSYLCERAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 3; MICRORNA; MICRORNA 106A; MICRORNA 135B; MICRORNA 155; MICRORNA 15B; MICRORNA 18B; MICRORNA 196B; MICRORNA 20B; MICRORNA 21; MICRORNA 218; MICRORNA 23A; MICRORNA 27; MICRORNA 29B; MICRORNA 29C; MICRORNA 31; MICRORNA 342 5P; MICRORNA 34A; MICRORNA 422A; MICRORNA 455 3P; MICRORNA 455 5P; MICRORNA 502; MICRORNA 708; MICRORNA 885 5P; MICRORNA 9; MICRORNA 93; MICRORNA 98; UNCLASSIFIED DRUG; TRANSCRIPTOME; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; B CELL CULTURE; B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CHILD; CONTROLLED STUDY; DOWN REGULATION; EVENT FREE SURVIVAL; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GERMINAL CENTER; GOLD STANDARD; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT FAILURE; UPREGULATION; CLASSIFICATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; TUMOR CELL LINE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84923308188     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-566778     Document Type: Article

References (51)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Iqbal J, Joshi S, Patel KN, et al. Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma. Indian J Cancer. 2007;44(2):72-86.
3. Bea S, Zettl A, Wright G, et al; Lymphoma/Leukemia Molecular Profiling Project. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve geneexpression- based survival prediction. Blood. 2005; 106(9):3183-3190.
4. Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004; 165(1):159-166.
5. Dave SS, Fu K, Wright GW, et al; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431-2442.
6. Hummel M, Bentink S, Berger H, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430.
7. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116-120.
8. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321-1325.
9. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104(10): 3009-3020.
10. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15(17):5494-5502.
11. de Jong D, Rosenwald A, Chhanabhai M, et al; Lunenburg Lymphoma Biomarker Consortium. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-812.
12. Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome prediction in diffuse large-Bcell lymphoma. N Engl J Med. 2009;360(26): 2794-2795.
13. Montes-Moreno S, Martinez N, Sanchez-Espiridión B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118(4): 1034-1040.
14. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17):9991-9996.
15. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004;2(4):E108.
16. Deffenbacher KE, Iqbal J, SangerW, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood. 2012;119(16):3757-3766.
17. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuselarge B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
18. Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
19. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large Bcell lymphomas. Blood. 2009;113(16):3754-3764.
20. Zhang J, Jima DD, Jacobs C, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009;113(19): 4586-4594.
21. Tan LP, Wang M, Robertus JL, et al. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest. 2009; 89(6):708-716.
22. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278-1284.
23. Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res. 2009;104(10):1184-1191.
24. Heise N, De Silva N, Carette A, Simonetti G, Bhagat G, Klein U. Differential expression and non-redundant functions of NF-kB transcription factor subunits in germinal center (GC) B cell subpopulations [abstract]. Blood. 2011;118(21). Abstract 216.
25. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43-50.
26. Simon R, Peng A. BRB-ArrayTools User Guide, Version 4.2.0-Beta-1. 2011. NIH, Washington DC.
27. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005; 102(10):3627-3632.
28. Huang X, Shen Y, Liu M, et al. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol. 2012;181(1):26-33.
29. Huang X, Meng B, Iqbal J, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2013;31(36): 4520-4528.
30. Iqbal J, Liu Z, Deffenbacher K, Chan WC. Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol. 2009;22(2):191-210.
31. Gatto D, Brink R. The germinal center reaction. J Allergy Clin Immunol. 2010;126(5):898-907; quiz 908-909.
32. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9(8):839-845.
33. Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160(5): 571-581.
34. Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010;37(2):367-376.
35. Hafner M, Landthaler M, Burger L, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010;141(1):129-141.
36. Scholtysik R, Kreuz M, Klapper W, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of Deutsche Krebshilfe. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica. 2010;95(12):2047-2055.
37. Tsai KW, Hu LY, Wu CW, et al. Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer. 2010; 49(11):969-980.
38. Bhatia S, Kaul D, Varma N. Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol Cell Biochem. 2010;340(1-2):97-106.
39. Teng G, Hakimpour P, Landgraf P, et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity. 2008;28(5):621-629.
40. Würdinger T, Tannous BA, Saydam O, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 2008;14(5):382-393.
41. Yeung ML, Yasunaga J, Bennasser Y, et al. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res. 2008; 68(21):8976-8985.
42. Lai KW, Koh KX, Loh M, et al; Singapore Gastric Cancer Consortium. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer. 2010;46(8):1456-1463.
43. Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011; 17(12):4125-4135.
44. Costinean S, Zanesi N, Pekarsky Y, et al. Pre- B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA. 2006; 103(18):7024-7029.
45. Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007; 121(5):1156-1161.
46. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142(5):732-744.
47. Jung I, Aguiar RC. MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. Br J Haematol. 2009;144(1):138-140.
48. Babar IA, Cheng CJ, Booth CJ, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA. 2012;109(26):E1695-E1704.
49. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 39-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108(13):4178-4186.
50. Hasselblom S, Hansson U, Olsson M, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol. 2010; 149(4):560-568.
51. Kong W, He L, Coppola M, et al. MicroRNA- 155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285(23):17869-17879.